Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Moderna Inc (MRNA)

NASDAQ
Currency in USD
Disclaimer
108.85
+0.96(+0.89%)
Closed
After Hours
108.82-0.03(-0.03%)

MRNA Comments

https://www.smarteranalyst.com/bloggers-corner/coronavirus-vaccine-maker-moderna-mrna-sparks-optimism-among-investors-heres-why/
As Livshits explained in her note, Moderna has already “received feedback from the FDA regarding its trial design,” and “has been manufacturing mRNA-1273 material in anticipation of a phase II trial for the past month” already.  Indeed, Livshits believes that “it is quite likely some older volunteers have already been dosed,” so the Phase 2 trial could almost be said to be underway already. The analyst notes further that “no major unexpected safety signals associated with the vaccination itself have been seen thus far,” which is certainly a promising way for the drug to be beginning its Phase 2 trials.
As Livshits explained in her note, Moderna has already “received feedback from the FDA regarding its trial design,” and “has been manufacturing mRNA-1273 material in anticipation of a phase II trial for the past month” already.  Indeed, Livshits believes that “it is quite likely some older volunteers have already been dosed,” so the Phase 2 trial could almost be said to be underway already. The analyst notes further that “no major unexpected safety signals associated with the vaccination itself have been seen thus far,” which is certainly a promising way for the drug to be beginning its Phase 2 trials.
 probably will rise to 50+ soon, before the 9/5. progress seems solid.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.